Arthritis Clinical Trials

This multicenter, open-label, single arm study will evaluate the safety of administering MabThera/Rituxan (rituximab) at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to anti-TNF therapy and are receiving methotrexate. Patients will receive 2 courses of MabThera/Rituxan separated by 24 weeks, a course consisting of two 1000 mg intravenous infusions of MabThera/Rituxan separated by 2 weeks. The Day 1 infusion will be administered at the labeled rate (4.25 hours), the Day 15 and Week 24 and 26 infusions over a 2-hour period. The anticipated time on study treatment is 26 weeks with a 4-week follow-up.